207 related articles for article (PubMed ID: 37737900)
1. The emerging role of the urinary microbiome in benign noninfectious urological conditions: an up-to-date systematic review.
Suarez Arbelaez MC; Monshine J; Porto JG; Shah K; Singh PK; Roy S; Amin K; Marcovich R; Herrmann TRW; Shah HN
World J Urol; 2023 Nov; 41(11):2933-2948. PubMed ID: 37737900
[TBL] [Abstract][Full Text] [Related]
2. Interplay between bladder microbiota and overactive bladder symptom severity: a cross-sectional study.
Li K; Chen C; Zeng J; Wen Y; Chen W; Zhao J; Wu P
BMC Urol; 2022 Mar; 22(1):39. PubMed ID: 35305613
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of an α
Herschorn S; Tarcan T; Jiang YH; Chung E; Abdul Hadi F; Steup A; Sumarsono B
Neurourol Urodyn; 2024 Mar; 43(3):604-619. PubMed ID: 38291827
[TBL] [Abstract][Full Text] [Related]
4. Vaginal estrogen therapy is associated with increased Lactobacillus in the urine of postmenopausal women with overactive bladder symptoms.
Thomas-White K; Taege S; Limeira R; Brincat C; Joyce C; Hilt EE; Mac-Daniel L; Radek KA; Brubaker L; Mueller ER; Wolfe AJ
Am J Obstet Gynecol; 2020 Nov; 223(5):727.e1-727.e11. PubMed ID: 32791124
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin in the treatment of OAB, BPH, and IC.
Smith CP
Toxicon; 2009 Oct; 54(5):639-46. PubMed ID: 19268490
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the urogenital microbiome in Miniature Schnauzers with and without calcium oxalate urolithiasis.
Coffey EL; Gomez AM; Burton EN; Granick JL; Lulich JP; Furrow E
J Vet Intern Med; 2022 Jul; 36(4):1341-1352. PubMed ID: 35796316
[TBL] [Abstract][Full Text] [Related]
7. Patterns of medical management of overactive bladder (OAB) and benign prostatic hyperplasia (BPH) in the United States.
Anger JT; Goldman HB; Luo X; Carlsson MO; Chapman D; Zou KH; Russell D; Ntanios F; Esinduy CB; Clemens JQ
Neurourol Urodyn; 2018 Jan; 37(1):213-222. PubMed ID: 28455944
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Mirabegron in Men with Overactive Bladder Symptoms and Benign Prostatic Hyperplasia.
Mullen GR; Kaplan SA
Curr Urol Rep; 2021 Jan; 22(1):5. PubMed ID: 33411109
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post-marketing study.
Takahashi S; Kato D; Tabuchi H; Uno S
Low Urin Tract Symptoms; 2021 Jan; 13(1):79-87. PubMed ID: 32761776
[TBL] [Abstract][Full Text] [Related]
10. Implications of the Genitourinary Microbiota in Prostatic Disease.
Bajic P; Dornbier RA; Doshi CP; Wolfe AJ; Farooq AV; Bresler L
Curr Urol Rep; 2019 May; 20(7):34. PubMed ID: 31104156
[TBL] [Abstract][Full Text] [Related]
11. The gut, vaginal, and urine microbiome in overactive bladder: a systematic review.
Sze C; Pressler M; Lee JR; Chughtai B
Int Urogynecol J; 2022 May; 33(5):1157-1164. PubMed ID: 35237854
[TBL] [Abstract][Full Text] [Related]
12. Calcium Oxalate Urolithiasis: A Case of Missing Microbes?
Batagello CA; Monga M; Miller AW
J Endourol; 2018 Nov; 32(11):995-1005. PubMed ID: 29808727
[TBL] [Abstract][Full Text] [Related]
13. Urobiome: An outlook on the metagenome of urological diseases.
Shoemaker R; Kim J
Investig Clin Urol; 2021 Nov; 62(6):611-622. PubMed ID: 34729961
[TBL] [Abstract][Full Text] [Related]
14. Evolving Role of Silodosin for the Treatment of Urological Disorders - A Narrative Review.
Jindan L; Xiao W; Liping X
Drug Des Devel Ther; 2022; 16():2861-2884. PubMed ID: 36051157
[TBL] [Abstract][Full Text] [Related]
15. Management of use of urinary antimuscarinics and alpha blockers for benign prostatic hyperplasia in older adults at risk of falls: a clinical review.
İlhan B; Erdoğan T; Topinková E; Bahat G;
Eur Geriatr Med; 2023 Aug; 14(4):733-746. PubMed ID: 37245173
[TBL] [Abstract][Full Text] [Related]
16. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study).
Yamanishi T; Kaga K; Sakata K; Yokoyama T; Kageyama S; Fuse M; Tokunaga S
Neurourol Urodyn; 2020 Feb; 39(2):804-812. PubMed ID: 31961963
[TBL] [Abstract][Full Text] [Related]
17. Comparative functional analysis of the urinary tract microbiome for individuals with or without calcium oxalate calculi.
Kachroo N; Monga M; Miller AW
Urolithiasis; 2022 Jun; 50(3):303-317. PubMed ID: 35234986
[TBL] [Abstract][Full Text] [Related]
18. [Pathophysiology and pharmacotherapy of benign prostatic disorders].
Aizawa N
Nihon Yakurigaku Zasshi; 2022; 157(3):164-167. PubMed ID: 35491110
[TBL] [Abstract][Full Text] [Related]
19. A 52-week multicenter randomized controlled study of the efficacy and safety of add-on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study).
Yamanishi T; Asakura H; Seki N; Tokunaga S
Low Urin Tract Symptoms; 2019 May; 11(3):115-121. PubMed ID: 30358116
[TBL] [Abstract][Full Text] [Related]
20. Effect of systemic atherosclerosis on overactive bladder symptoms in men with benign prostatic hyperplasia.
Lee D; Koo KC; Yoo JW; Lee KS
Low Urin Tract Symptoms; 2022 Jan; 14(1):35-40. PubMed ID: 34323012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
